Background/Aim: Amaranth is a source of several bioactive compounds, among which peptides with inhibitory activity upon dipeptidyl peptidase IV (DPP-IV) have been reported. However, there is no information about the action of amaranth DPP-IV-inhibitory peptides using in vivo models. The aim of this work was to evaluate the effect of amaranth consumption on plasma and kidney DPP-IV activity as well the changes in plasma proteome profile of streptozotocin (STZ)-induced hyperglycemic rats. Methods: Rats were fed for 12 weeks with a diet containing 20% popped amaranth grain. Kidneys and blood samples were collected for lipid profile, DPP-IV activity and expression, and proteomic analysis. Results: Total cholesterol and DPP-IV activity in plasma was increased in hyperglycemic rats, but this effect was reverted by amaranth consumption. Triacylglycerols were increased in the hyperglycemic group fed amaranth, and the highest levels of high-density lipoproteins were also observed in this group. These data correlated with the accumulation of apolipoprotein A-II in plasma. Accumulation of the antioxidant protein paraoxonase/arylesterase 1 in STZ-induced hyperglycemic rats was observed when amaranth was supplied in the diet. Conclusion: This study provides new insights into the molecular mechanisms by which amaranth exerts its beneficial health action in a hyperglycemic state.

Keywords:
Amaranth, Hyperglycemia, Dipeptidyl peptidase IV activity, Plasma proteome, Plasma lipid profile
1.
Ozen AE, Pons A, Tur JA: Worldwide consumption of functional foods: a systematic review. Nutr Rev 2012; 70: 472–481.
2.
Ferguson LR: Nutrigenomics approaches to functional foods. J Am Diet Assoc 2009; 109: 452–458.
3.
Rastogi A, Shukla S: Amaranth: a new millennium crop of nutraceutical values. Crit Rev Food Sci Nutr 2013; 53: 109–125.
4.
Caselato-Sousa VM, Amaya-Farfan J: State of knowledge on amaranth grain: a comprehensive review. J Food Sci 2012; 77:R93–R104.
5.
Velarde-Salcedo AJ, Barrera-Pacheco A, Lara-Gonzalez S, Montero-Moran GM, Diaz-Gois A, Gonzalez de Mejia E, Barba de la Rosa AP: In vitro inhibition of dipeptidyl peptidase IV by peptides derived from the hydrolysis of amaranth (Amaranthus hypochondriacus L.) proteins. Food Chem 2013; 136: 758–764.
6.
Drab SR: Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010; 30: 609–624.
7.
Matteucci E, Giampietro O: Dipeptidyl peptidase-4 inhibition: linking chemical properties to clinical safety. Curr Med Chem 2011; 18: 4753–4760.
8.
Fan J, Johnson MH, Lila MA, Yousef G, de Mejia EG: Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management. Evid Based Complement Alternat Med 2013; 2013: 479505.
9.
Pischetsrieder M, Baeuerlein R: Proteome research in food science. Chem Soc Rev 2009; 38: 2600–2608.
10.
Zambotti-Villela L, Yamasaki SC, Villarroel JS, Alponti RF, Silveira PF: Prospective evaluation of aminopeptidase activities in plasma and peripheral organs of streptozotocin-induced diabetic rats. J Endocrinol Invest 2008; 31: 492–498.
11.
Farvin KH, Anandan R, Kumar SH, Shiny KS, Mathew S, Sankar TV, Nair PG: Cardioprotective effect of squalene on lipid profile in isoprenaline-induced myocardial infarction in rats. J Med Food 2006; 9: 531–536.
12.
Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, Sugiyama Y: Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 2003; 139: 911–918.
13.
Miettinen TA, Gylling H, Tuominen J, Simonen P, Koivisto V: Low synthesis and high absorption of cholesterol characterize type 1 diabetes. Diabetes Care 2004; 27: 53–58.
14.
Alessa T, Szeto A, Chacra W, Mendez A, Goldberg RB: High HDL-C prevalence is common in type 1 diabetes and increases with age but is lower in Hispanic individuals. J Diabetes Complications 2015; 29: 105–107.
15.
Mendonca S, Saldiva PH, Cruz RJ, Areas JAG: Amaranth protein presents cholesterol-lowering effect. Food Chem 2009; 116: 738–742.
16.
Blaslov K, Bulum T, Duvnjak L: Circulating dipeptidyl peptidase-4 activity is associated with insulin resistance in type 1 diabetic patients. J Diabetes Complications 2015; 29: 390–394.
17.
Yang J, Campitelli J, Hu G, Lin Y, Luo J, Xue C: Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007; 81: 272–279.
18.
Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y: Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009; 200: 53–61.
19.
Zhang C, Meng Y, Liu Q, Xuan M, Zhang L, Deng B, Zhang K, Liu Z, Lei T: Injury to the endothelial surface layer induces glomerular hyperfiltration rats with early-stage diabetes. J Diabetes Res 2014; 2014: 953740.
20.
Mikaelian NP, Gurina AE, Terent’ev AA: Dysfunction of membrane-receptor system of blood cells and kidney tissue in experimental diabetes mellitus. Bull Exp Biol Med 2013; 154: 610–613.
21.
Miko M, Jakubovsky J, Vrabcova M, Varga I: Ultrastructural changes of kidney in diabetic rats. Bratisl Lek Listy 2016; 117: 161–165.
22.
Kim HK, Kim MJ, Cho HY, Kim EK, Shin DH: Antioxidative and anti-diabetic effects of amaranth (Amaranthus esculantus) in streptozotocin-induced diabetic rats. Cell Biochem Funct 2006; 24: 195–199.
23.
Mentlein R: Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9–24.
24.
Matteucci E, Giampietro O: Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. Curr Med Chem 2009; 16: 2943–2951.
25.
Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y: DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58: 157–166.
26.
Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Reboucas NA: Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008; 294:F414–F422.
27.
Hillmeister P, Persson PB: The kallikrein-kinin system. Acta Physiol (Oxf) 2012; 206: 215–219.
28.
Kaplan AP, Ghebrehiwet B: The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47: 2161–2169.
29.
Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI, Whisstock JC: An overview of the serpin superfamily. Genome Biol 2006; 7: 216.
30.
Heit C, Jackson BC, McAndrews M, Wright MW, Thompson DC, Silverman GA, Nebert DW, Vasiliou V: Update of the human and mouse SERPIN gene superfamily. Hum Genomics 2013; 7: 22.
31.
Levy JH, Szlam F, Tanaka KA, Sniecienski RM: Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261–274.
32.
Mahendra JV, Kumar SD, Anuradha TS, Talikoti P, Nagaraj RS, Vishali V: Plasma fibrinogen in type 2 diabetic patients with metabolic syndrome and its relation with ischemic heart disease (IHD) and retinopathy. J Clin Diagn Res 2015; 9:BC18–BC21.
33.
Maiga SF, Kalopissis AD, Chabert M: Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes. Biochimie 2014; 96: 56–66.
34.
Villeneuve S, Brisson D, Marchant NL, Gaudet D: The potential applications of apolipoprotein E in personalized medicine. Front Aging Neurosci 2014; 6: 154.
35.
van Himbergen TM, van Tits LJ, Roest M, Stalenhoef AF: The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine. Neth J Med 2006; 64: 34–38.
36.
Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M: Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008; 56: 8704–8713.
37.
Rosenblat M, Aviram M: Paraoxonases role in the prevention of cardiovascular diseases. Biofactors 2009; 35: 98–104.
38.
Rosenblat M, Hayek T, Aviram M: Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 2006; 187: 363–371.
39.
James RW, Deakin SP: The contribution of high density lipoprotein apolipoproteins and derivatives to serum paraoxonase-1 activity and function. Adv Exp Med Biol 2010; 660: 173–181.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.